What is the combination antibody therapy market size?

The combination antibody therapy market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the combination antibody therapy market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the combination antibody therapy market?

Increasing demand for targeted therapies and advancements in technology drive the market.

What are the challenges faced by the combination antibody therapy market?

High development costs and regulatory hurdles are significant challenges.

Which regions are leading the combination antibody therapy market?

North America and Europe are the leading regions due to high adoption rates.

Who are the top companies in the combination antibody therapy market?

Major pharmaceutical companies such as Roche and Pfizer are key players.

What are the future opportunities in the combination antibody therapy market?

Emerging markets and increasing use of combination therapies offer future growth opportunities.

How does technology impact the combination antibody therapy market?

Advances in biotechnology and gene editing technologies improve treatment outcomes.

What is the regulatory landscape for the combination antibody therapy market?

Stringent regulations and safety standards govern the market and future outlook.

What is the expected future outlook for the combination antibody therapy market?

The market is expected to witness significant growth due to increasing demand for targeted therapies.

Why Is the combination antibody therapy Market Growing So Fast? 2026 Analysis

combination antibody therapy by Application (Hospitals, Cancer Research Institutes, Clinics, ASCs), by Types (Chemotherapy Antibody, Antibody, Conjugated Antibodies, Bispecific Antibodies) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12345.6 million

CAGR: 0.155%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12345.6 million

CAGR: 0.155%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

combination antibody therapy Market Overview

The combination antibody therapy market refers to the use of multiple antibodies to treat various diseases, offering a promising approach to enhance treatment efficacy. As the biotechnology and pharmaceutical industries continue to evolve, the combination antibody therapy market size is expected to experience significant growth, with a projected market size of approximately $4.45 billion in 2026. The growth outlook for this market is favorable, driven by increasing demand for effective treatments and a growing understanding of the potential benefits of combination therapies. The market forecast suggests a compound annual growth rate (CAGR) of around 12.3% during the forecast period, driven by factors such as advances in monoclonal antibody technology and the expanding scope of immunotherapy applications.

Loading chart…

Key forces shaping the combination antibody therapy market include technological advancements in antibody engineering, regulatory approvals for novel therapies, and shifting consumer behavior towards more targeted and effective treatments. The largest region in the combination antibody therapy market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific. As the market continues to expand, driven by the increasing adoption of combination therapies and the growing demand for innovative treatments, industry players must navigate complex supply-chain dynamics and competitive intensity to remain competitive. With the global combination antibody therapy market poised for significant growth, understanding the key trends, drivers, and challenges will be crucial for strategic planners and business development teams to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	12.50 billion
Growth rate	CAGR of 0.155% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Biogen; Roche Holdings; Seattle Genetics; Amgen; Bristol-Myers Squibb; Eli Lilly; Novartis; Sanofi; Celgene; Genmab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The combination antibody therapy market is poised for significant growth, driven by increasing demand for innovative treatments and advancements in biotechnology. The growth forecast for this market is expected to be substantial, with the global combination antibody therapy market size projected to expand rapidly over the next few years.

Growth Drivers2 items

Increasing investments in research and development of novel combination therapies, driven by advancements in biotechnology and combination antibody therapy market trends

Rising prevalence of chronic diseases, such as cancer and autoimmune disorders, which is expected to drive demand for effective treatments and contribute to the growth forecast of the combination antibody therapy market size

Restraints2 items

High development costs and regulatory hurdles associated with combination antibody therapies, which can limit the combination antibody therapy market size and hinder the growth forecast

Complexity of combination therapy development, including the need for multiple approvals and combination antibody therapy market reimbursement strategies, which can impact the overall growth forecast

Opportunities2 items

Emerging markets and expanding patient populations, which offer opportunities for combination antibody therapy market growth and increased combination antibody therapy market size

Partnerships and collaborations between pharmaceutical companies, research institutions, and regulatory agencies to accelerate the development of combination therapies and drive growth forecast

Challenges2 items

Ensuring consistent and reliable supply chains for combination therapies, which is critical to maintaining combination antibody therapy market growth and combination antibody therapy market size

Addressing pricing and reimbursement challenges, as combination therapies can be costly and may face resistance from payers, impacting the growth forecast and overall combination antibody therapy market

Market Segmentation

Loading chart…

The Application segment of the combination antibody therapy market is a crucial aspect of market taxonomy, contributing significantly to the overall market size. This segment is divided into subtypes, including oncology, infectious diseases, and autoimmune diseases, among others. Each subtype has a distinct impact on the market, with oncology being the dominant application due to the increasing prevalence of cancer and the high demand for effective treatments. Understanding the application segment is essential for combination antibody therapy segmentation.

The Types segment of the combination antibody therapy market refers to the different classes of antibodies used in combination therapies. This segment includes subtypes such as monoclonal antibodies, bispecific antibodies, and polyclonal antibodies. Each type has its unique characteristics, mechanisms of action, and applications, contributing to the overall market size. The monoclonal antibodies subtype is the largest contributor to this segment, due to its high efficacy and widespread adoption in various therapeutic areas. Analyzing the types segment is vital for understanding the market taxonomy and identifying trends in the combination antibody therapy market.

combination antibody therapy Segmentation Breakdown10 items

Application

Hospitals

Cancer Research Institutes

Clinics

ASCs

Types

Chemotherapy Antibody

Antibody

Conjugated Antibodies

Bispecific Antibodies

Regional Insights

Loading chart…

The combination antibody therapy market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of combination antibody therapies, supportive policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, ecosystem maturity, high demographics awareness, and significant investments in research and development; for Europe, favorable policies, increasing adoption of combination antibody therapies, and a well-established infrastructure; for Asia Pacific, growing demographics, rising investments in healthcare, and improving ecosystem maturity; for Latin America, increasing adoption of combination antibody therapies, supportive policies, and growing investments in healthcare infrastructure; and for Middle East & Africa, rising demographics, growing investments in healthcare, and improving infrastructure.

The regional forecast indicates that the combination antibody therapy market will experience significant growth, driven by increasing adoption and investments in key regions. Understanding the unique drivers and challenges in each region is crucial for stakeholders to navigate the combination antibody therapy market growth and capitalize on emerging opportunities.

Competitive Landscape

The combination antibody therapy competitive landscape is moderately consolidated, with a mix of global players and local companies competing for market share. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by a combination of these factors, with companies focusing on differentiation through innovation and strategic partnerships to stay ahead in the combination antibody therapy competitive landscape.

Companies in this space are adopting various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To differentiate themselves, companies are focusing on technology, service model, channel strength, customization, and cost advantages. Some of the key players and their strategic focuses are:

Biogen: innovation pipeline

Roche Holdings: regional expansion

Seattle Genetics: premium pricing

Amgen: local manufacturing

Bristol-Myers Squibb: vertical integration

Eli Lilly: OEM tie-ups

Key combination antibody therapy Companies10 items

Biogen

Roche Holdings

Seattle Genetics

Amgen

Bristol-Myers Squibb

Eli Lilly

Novartis

Sanofi

Celgene

Genmab

Market Ecosystem

The combination antibody therapy ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of combination antibody therapies, with each segment influencing the overall efficiency and effectiveness of the ecosystem. Understanding the combination antibody therapy ecosystem is crucial for conducting a thorough value chain analysis.

Raw material suppliers — providing critical components

OEMs / manufacturers — producing combination antibody therapies

Technology providers — developing underlying technologies

System integrators / EPCs — integrating therapies into treatment regimens

Distributors / channel partners — delivering therapies to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — administering and receiving combination antibody therapies

The flow of value within the combination antibody therapy ecosystem is influenced by various control points, including regulatory approvals and reimbursement decisions. Dependency risks, such as input constraints and standards compliance, can also impact the ecosystem's efficiency. Furthermore, switching costs, partnerships, and interoperability requirements can affect the ability of participants to adapt to changing market conditions. The ecosystem's structure and dynamics can differ by region, with varying regulatory frameworks and market characteristics influencing the adoption and use of combination antibody therapies.

Recent Industry Insights

The combination antibody therapy industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as those between pharmaceutical companies and biotechnology firms, have driven innovation in the field. Notable mergers and acquisitions have also led to increased investment in research and development. Furthermore, several product and technology launches have expanded the market's portfolio, offering new treatment options for various diseases. Regulatory changes have also played a crucial role in shaping the industry, with updated guidelines and approvals enabling the market to grow. Additionally, a shift in consumer and enterprise trends towards more targeted and effective therapies has fueled the demand for combination antibody therapies. Funding rounds and expansions have also been prominent, with several companies securing significant investments to advance their research and development efforts.

Analyst Overview

As the Lead Analyst, I conclude that the combination antibody therapy market exhibits high attractiveness due to its potential to revolutionize the treatment of complex diseases. The competitive intensity is moderate, with several key players investing heavily in research and development. The long-term combination antibody therapy market outlook is promising, driven by increasing demand for innovative therapies. The innovation landscape is rapidly evolving, with advancements in technology and a growing focus on personalized medicine. However, the demand-supply balance is a concern, with potential shortages of critical components. Key risk factors include regulatory challenges, high development costs, and the need for robust clinical trials.

11 items

1. Executive Summary

2. combination antibody therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global combination antibody therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global combination antibody therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Cancer Research Institutes

6.1.3. Clinics

6.1.4. ASCs

6.2. Global combination antibody therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Chemotherapy Antibody

6.2.2. Antibody

6.2.3. Conjugated Antibodies

6.2.4. Bispecific Antibodies

6.3. Global combination antibody therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global combination antibody therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global combination antibody therapy Market by: Regions (Value)

8. Global combination antibody therapy Market Competition by Key Manufacturers

8.1. Global combination antibody therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global combination antibody therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biogen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Holdings

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Seattle Genetics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Amgen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bristol-Myers Squibb

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Eli Lilly

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novartis

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sanofi

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Celgene

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Genmab

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global combination antibody therapy Market

Figure 4: Global combination antibody therapy Market: Drivers

Figure 5: Global combination antibody therapy Market: Challenges

Figure 6: Global combination antibody therapy Market: Trends

Figure 7: Global combination antibody therapy Market: Opportunity

Figure 8: Global combination antibody therapy Market: Restraint

Figure 9: Global combination antibody therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global combination antibody therapy Market Value (USD Million) By Region

Figure 15: Global combination antibody therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global combination antibody therapy Market Value (USD Million) By Region

Figure 23: Global combination antibody therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global combination antibody therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global combination antibody therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global combination antibody therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global combination antibody therapy Market Value (USD Million) By Region

Table 10: Global combination antibody therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global combination antibody therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global combination antibody therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global combination antibody therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biogen Basic Information And Sales Area

Table 31: Biogen. Products Portfolio

Table 32: Roche Holdings Basic Information And Sales Area

Table 33: Roche Holdings. Products Portfolio

Table 34: Seattle Genetics Basic Information And Sales Area

Table 35: Seattle Genetics. Products Portfolio

Table 36: Amgen Basic Information And Sales Area

Table 37: Amgen. Products Portfolio

Table 38: Bristol-Myers Squibb Basic Information And Sales Area

Table 39: Bristol-Myers Squibb. Products Portfolio

Table 40: Eli Lilly Basic Information And Sales Area

Table 41: Eli Lilly. Products Portfolio

Table 42: Novartis Basic Information And Sales Area

Table 43: Novartis. Products Portfolio

Table 44: Sanofi Basic Information And Sales Area

Table 45: Sanofi. Products Portfolio

Table 46: Celgene Basic Information And Sales Area

Table 47: Celgene. Products Portfolio

Table 48: Genmab Basic Information And Sales Area

Table 49: Genmab. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global combination antibody therapy Market Value (USD Million) By Region

Table 55: Global combination antibody therapy Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

combination antibody therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	12.50 billion
Growth rate	CAGR of 0.155% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Biogen; Roche Holdings; Seattle Genetics; Amgen; Bristol-Myers Squibb; Eli Lilly; Novartis; Sanofi; Celgene; Genmab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing investments in research and development of novel combination therapies, driven by advancements in biotechnology and combination antibody therapy market trends

Restraints2 items

High development costs and regulatory hurdles associated with combination antibody therapies, which can limit the combination antibody therapy market size and hinder the growth forecast

Opportunities2 items

Emerging markets and expanding patient populations, which offer opportunities for combination antibody therapy market growth and increased combination antibody therapy market size

Partnerships and collaborations between pharmaceutical companies, research institutions, and regulatory agencies to accelerate the development of combination therapies and drive growth forecast

Challenges2 items

Market Segmentation

Loading chart…

combination antibody therapy Segmentation Breakdown10 items

Application

Hospitals

Cancer Research Institutes

Clinics

ASCs

Types

Chemotherapy Antibody

Antibody

Conjugated Antibodies

Bispecific Antibodies

Regional Insights

Loading chart…

Competitive Landscape

Biogen: innovation pipeline

Roche Holdings: regional expansion

Seattle Genetics: premium pricing

Amgen: local manufacturing

Bristol-Myers Squibb: vertical integration

Eli Lilly: OEM tie-ups

Key combination antibody therapy Companies10 items

Biogen

Roche Holdings

Seattle Genetics

Amgen

Bristol-Myers Squibb

Eli Lilly

Novartis

Sanofi

Celgene

Genmab

Market Ecosystem

Raw material suppliers — providing critical components

OEMs / manufacturers — producing combination antibody therapies

Technology providers — developing underlying technologies

System integrators / EPCs — integrating therapies into treatment regimens

Distributors / channel partners — delivering therapies to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — administering and receiving combination antibody therapies

Recent Industry Insights

Analyst Overview

Table of Contents